Global respiratory complications market to exceed $30 billion by 2022; Report

The respiratory complications market is set to grow from $21.8 billion in 2015 to $30.2 billion by 2022, representing a compound annual growth rate of 4.7%.

According to business intelligence provider GBI Research’s latest report, despite a small late-stage pipeline, the space will see a relatively strong rise in value due to sales of products already on the market. Indeed, the approval of pipeline products is expected to have a limited impact on the market during the forecast period.

Yasser Mushtaq, senior analyst for GBI Research, explains: “There are few drugs that generate substantial revenue in the current respiratory complications market, with only one generating over $1 billion from revenues specific to these complications. This is the Prevnar family pneumococcal disease vaccine, which has been approved for a broad spectrum of patients and generated $6.3 billion in 2015, a level of revenue which is expected to remain relatively stable over the forecast period.”